Thu, March 16th 2023
​
ProtonDx Welcomes New CFO, Ann Wong, to Drive Scale-up and Commercial Expansion
​
Ann Wong brings extensive experience of scaling organisations and leading finance operations
London, UK – 16th March 2023 – Today, ProtonDx — an in vitro diagnostics company designing, manufacturing, and marketing rapid, accurate, multi‑pathogen, point‑of‑care diagnostic solutions — announced the appointment of its new Chief Finance Officer, Ann Wong.
​
Ann is an executive with a proven track record in scaling international businesses and leading finance operations. Having held various leadership positions at corporates and early‑stage businesses, including KPMG and NBC Universal, she has extensive experience of setting up and growing new operations internationally. Ann joins ProtonDx as full‑time CFO from an R&D‑led agri‑food tech start‑up, where she remains a Non‑Executive Director.
Ann Wong, CFO, ProtonDx stated:
I am excited to work with this world‑class, interdisciplinary team of biochemists, engineers, and diagnostics experts who are dedicated to bringing fast, accurate, affordable diagnostics to the global healthcare market. I have scaled businesses around the world in intrapreneurial roles, including setting up a new operation in China and growing it to 70‑strong, and growing a new division from 20 to 200 people across 10 countries while integrating a significant acquisition. I also understand the opportunities and trade‑offs of early‑stage businesses, having persevered through the pandemic and the “VC winter” in my last role. I am pleased to leverage my experience to help ProtonDx disrupt point‑of‑care diagnostics and to realise the commercial potential of the Dragonfly and Lacewing platforms."
As CFO, Ann will bring further rigour to strategy, finance, and execution at ProtonDx, including refining supply chain and operational excellence.
Bob Enck, Chairman, ProtonDx stated:
​
"We are thrilled to welcome Ann on board as a key member of our leadership team. Efficiently and effectively building our organisation will be crucial to the continued commercial success of our innovative, disruptive technologies. Ann’s demonstrated track record of business expansion and financial rigour in both small and large organisations will serve our firm well as ProtonDx progresses into major markets including the EU, UK, and US.”
CE‑IVD marked and UK CTDA approved, Dragonfly is a rapid, accurate, molecular diagnostic system able to identify multiple viral pathogens at the point‑of‑care. Its revolutionary approach allows severe acute respiratory syndrome coronavirus 2 (SARSCoV2), influenza A virus (IAV), influenza B virus (IBV), respiratory syncytial virus (RSV) and human rhinovirus (HRV) to be detected from single respiratory swab. The system is poised to revolutionise rapid infectious disease detection and tracking worldwide.
​
Lacewing is an in vitro diagnostic platform that is in development by ProtonDx.